Study investigators note their meta-analysis may be the first to demonstrate the importance of interventions to support adherence to adjuvant endocrine therapy for breast cancer.
Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the NATALEE trial, which evaluated adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.